Survivin-derived peptide presented by HLA class I (Survivin-HLA-I)

Survivin-derived peptide presented by HLA class I is a tumor-associated antigen complex consisting of short amino acid sequences from the Survivin protein (BIRC5) bound to the groove of Human Leukocyte Antigen (HLA) class I molecules (UniProt O15392). Survivin is a member of the inhibitor of apoptosis (IAP) family that is highly expressed in nearly all human malignancies but is largely absent in differentiated normal adult tissues, making it an ideal target for cancer immunotherapy (PubMed: 15150571). These peptide-HLA complexes are displayed on the surface of cancer cells, where they can be recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes. Therapeutic strategies targeting this complex include peptide vaccines, such as SurVaxM and DPX-Survivac, as well as engineered TCR-T cell therapies and bispecific molecules (ClinicalTrials.gov: NCT02455227). By stimulating or providing an immune response against these specific epitopes, these treatments aim to selectively eliminate survivin-overexpressing tumor cells while sparing healthy tissue. Clinical development has focused on various solid tumors, including glioblastoma and ovarian cancer, where survivin expression correlates with poor prognosis and treatment resistance (PubMed: 29158371).

Other names

BIRC5 peptide-MHC class I complexSurvivin-HLA-A*02:01 complexSurvivin-derived epitopeSurvivin-MHC class I complexBaculoviral IAP repeat-containing protein 5 peptide-HLA complex

Induction of a cytotoxic T-lymphocyte (CTL) response through the recognition of survivin-derived epitopes presented on HLA class I molecules, leading to the selective lysis of survivin-overexpressing tumor cells.